Local delivery of chemotherapy: A supplement to existing cancer treatments. A case for surgical pastes and coated stents

Advanced Drug Delivery Reviews

Volumn 26, Issue 2-3, 1997, Pages 199-207

  Hunter, William L ^a   Burt, Helen M ^a,b   Machan, Lindsay ^c  

^a Angiotech Pharmaceuticals Inc   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Biodegradable polymers; Implantables; Paclitaxel; Sustained release

Indexed keywords

BIODEGRADATION; BIOMATERIALS; COATED MATERIALS; ONCOLOGY; POLYMERS; SURGERY; TOXICITY;

STENTS; SURGICAL PASTES;

CONTROLLED DRUG DELIVERY;

PACLITAXEL; POLYMER;

CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG IMPLANT; HUMAN; PASTE; PRIORITY JOURNAL; REVIEW; STENT; SUSTAINED RELEASE PREPARATION;

EID: 0031558232     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(97)00035-5     Document Type: Review

References (45)

1. H.D. Suit, Statement of the problem pertaining to the effect of dose fractionation and total treatment on the response to x-radiation, in: Time and Dose Relationships in Radiation Biology as Applied to Radiotherapy, Brookhaven National Laboratory Report 50203 (C-57), Uptown, NY, 1969.
2. V.T. Devita, Jr., S. Hellman, S.A. Rosenberg (Eds.), Cancer: Principles and Practice of Oncology, 3rd ed, J.B. Lippincott Co., Philadelphia, 1989.
3. P.H. Wiernik, E.L. Schwartz, J.J. Strauman, Phase I clinical and pharmacokinetic study of paclitaxel. Cancer Res. 47 (1987) 2486-2493.
4. D. Kelsen, J. Ajani, D. Ilson, K. Daugherty, R. Pazdur, A phase II trial of paclitaxel in advanced esophageal cancer: preliminary report. Semin. Oncol. 21(5) (1994) 44-48.
5. M.E. Stearns, M. Wang, Paclitaxel blocks processes essential for prostate tumour cell (PC3 ML) invasion and metastases. Cancer Res. 52 (1992) 3776-3781.
6. A. Morgan, G.V. Kulkarni, W.L. Hunter, C.A.G. McCulloch, T.F. Cruz, Taxol selectively induces mitotic arrest and apoptosis in proliferating synoviocytes. Arthritis Rheum. (1997) in press.
7. P.B. Schiff, S.B. Horwitz, Paclitaxel stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA 77 (1980) 1561-1565.
8. S.B. Horwitz, J. Parness, P.B. Schiff, J.J. Manfredi, Paclitaxel: a new probe for studying the structure and function of microtubules. Cold Spring Harbor Symp. Quant. Biol. 46 (1982) 227-240.
9. A.M. Oktaba, A.L. Arsenault, W.L. Hunter, Taxol: a potent inhibitor of normal and tumor-induced angiogenesis. Proc. Am. Assoc. Cancer Res. 36 (1995) 454.
10. E.K. Rowinsky, L.A. Cazenave, R.C. Donehower, Taxol: a novel investigational anti-microtubule agent. J. Natl. Cancer Inst. 82(15) (1990) 1247-1259.
11. A. Sharma, E. Mayhew, R.M. Straubinger, Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res. 53 (1993) 5877-5881.
12. A. Sharma, R.M. Straubinger, Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm. Res. 11(6) (1994) 889-895.
13. B.D. Tarr, T.G. Sambanden, S.H. Yalkowsky, A new parenteral emulsion for the administration of taxol. Pharm. Res. 4 (1987) 162-165.
14. M.H. Bartoli, M. Boitard, H. Fessi, H. Beriel, J.P. Devissaguet, F. Picot, F. Puisieux, In vitro and in vivo antitumoral activity of free, and encapsulated paclitaxel. J. Microencapsulation 7 (1990) 191-197.
15. T. Cserhati, J. Hollo, Interaction of taxol and other anticancer drugs with hydroxypropy-β-cyclodextrin. Int. J. Pharm. 108 (1994) 64-75.
16. S. Dordunoo, H.M. Burt, Solubility and stability of taxol effects of buffers and cyclodextrins. Int. J. Pharm. 133 (1996) 191-201.
17. W.C. Rose, Taxol: a review of its preclinical in vivo antitumor activity. Anticancer Drugs 3 (1992) 311-321.
18. J.A. O'Shaughnessy, J.S. Fisherman, K.H. Cowan, Combination paclitaxel (Taxol) and doxorubicin therapy for metastatic breast cancer. Semin. Oncol. 21(5 suppl. 8) (1994) 19-23.
19. F.H. Hochberg, A. Pruitt, Assumptions in the radiotherapy of glioblastoma. Neurology 30 (1980) 907-911.
20. K.E. Wallner, J.H. Galicich, G. Krol, E. Arbit, M.G. Malkin, Patterns of failure following treatment for glioblastoma multi-forme and anaplastic astrocytoma. Int. J. Radiat. Oncol. Biol. Phys. 16 (1988) 1405-1409.
21. K.A. Walter, M.A. Cahan, A. Gur, B. Tyler, J. Hilton, O.M. Colvin, P.C. Burger, A. Domb, H. Brem, Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res. 54 (1994) 2207-2212.
22. E.K. Rowinsky, P.J. Burke, J.E. Karp, R.W. Tucker, D.S. Ellinger, R. S. Donehower, Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res. 49 (1989) 4640-4647.
23. 3H-taxol in the rat. Proc. Am. Assoc. Cancer Res. 34 (1993) 381.
24. H. Brem, S. Piantaaosi, P.C. Burger, M. Walker, R. Selker, N.A. Vick, K. Black, M. Sisti, S. Brem, G. Mohr, Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery of biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345 (1995) 1008-1012.
25. O. Kubo, Y. Tajika, Y. Muragaki, H. Hiyama, K. Takakura, M. Yoshida, M. Kumakura, Local chemotherapy with slowly-releasing anti-cancer drug-polymers for malignant brain tumors. J. Control. Release 32 (1994) 1-8.
26. C.G. Pitt, Poly-∈-caprolactone and its copolymers, in: M. Chasin, R. Langer (Eds.), Biodegradable Polymers as Drug Delivery Systems, Marcel Dekker, New York, 1990, pp. 71-120.
27. C.G. Pitt, M.M. Gratzl, A.R. Jeffcoat, R. Zweidinger, A. Schindler, Sustained drug delivery systems II: factors affecting release rates from poly(∈-caprolactone) and related biodegradable polyesters. J. Pharm. Sci. 68 (1979) 1534-1538.
28. G. Perego, G.D. Cella, N.N. Aldini, M. Fini, R. Giardino, Preparation of a new nerve guide from a poly(L-lactide-co-6-caprolactone). Biomaterials 15 (1994) 189-193.
29. C.G. Pitt, M.M. Gratzl, G.L. Kimmel, J. Surles, A. Schindler, Aliphatic polyesters II. The degradation of poly(DL-lactide), poly(∈-caprolactone), and their copolymers in vivo. Biomaterials 2 (1981) 215-220.
30. S.C. Woodward, P.S. Brewer, F. Moatamed, A. Schindler, C.G. Pitt, The intracellular degradation of poly(∈-caprolactone). J. Biomed. Mater. Res. 19 (1985) 437-444.
31. C.I. Winternitz, J.K. Jackson, A.M. Oktaba, H.M. Burt, Development of a polymeric surgical paste formulation for taxol. Pharm. Res. 13(3) (1996) 368-375.
32. S.K. Dordunoo, A.M.C. Oktaba, W. Hunter, W. Min, T. Cruz, H.M. Burt, Release of taxol from poly(∈-caprolactone) pastes: effect of water-soluble additives. J. Control. Release 44 (1997) 87-96.
33. X. Zhang, J.K. Jackson, W. Wong, W. Min, T. Cruz, H.M. Burt, Development of biodegradable polymeric paste formulations for taxol: an in vitro and in vivo study. Int. J. Pharm. 137 (1996) 199-208.
34. J.K. Jackson, W. Min, T. Cruz, S. Cindric, L. Arsenault, D. Von Hoff, D. Degon, W. Hunter, H.M. Burt, A polymer based drug delivery system for the antineoplastic agent bis(maltolato) oxovanadium in mice, Br. J. Cancer (1996) in press.
35. J.L. Peacock, J.W. Keller, R.F. Asbury, Alimentary Cancer, in: P. Rubin (Ed.), Clinical Oncology: A Multidisciplinary Approach for Physicians and Students, 7th ed., W.B. Saunders Co., Philadelphia, PA, 1993, pp. 557-596.
36. H.C. Umpleby, R.C.W. Williamson, Anatomic recurrence in large bowel cancer. Br. J. Surg. 74 (1987) 873-878.
37. W. Molnar, A.E. Stockum, Relief of obstructive jaundice through percutaneous transhepatic catheter: a new therapeutic method. Am. J. Roentgenol. 123 (1974) 356-367.
38. C.H. Carnasco, S. Wallace, C. Charnsangavej, Expandable biliary endoprosthesis: an experimental study. Am. J. Roentgenol. 145 (1985) 1279-1281.
39. R. Alvarado, J.C. Palmaz, O.J. Garcia, O.T. Fermin, C.R. Rees, Evaluation of polymer-coated balloon-expandable stents in bile ducts. Radiology 170 (1989) 975-978.
40. W. Cwikiel, H. Stridbeck, U. Stenram, Electrolytic stents to inhibit tumor growth: experimental study in vitro and in rats. Acta Radiol. 34 (1993) 258.
41. T.A. Fischell, B.K. Kharma, D.R. Fischell, Low dose, β-particle emission from 'stent' wire results incomplete; localized inhibition of smooth muscle cell proliferation. JVIR 6 (1996) 296.
42. A.M. Lincoff, E.J. Topol, S.G. Ellis, Local drug delivery for the prevention of restenosis. Fact, fancy and future. Circulation 90 (1994) 2070-2084.
43. J. Folkman, M. Hochberg, Self-regulation of growth in three dimensions. J. Exp. Med. 138 (1973) 745-753.
44. L. Machan, J. Jessurun, A.L. Arsenault, W.L. Hunter, Angiogenesis inhibitor coated metallic stents in the porcine duct -prevention of benign reactive overgrowth. Proceedings of the Radiological Society of North America, 1995.
45. L.S. Machan, W.L. Hunter, Presented at the Cardiovascular and Interventional Radiology Society of Europe Annual Meeting, Madiera, Portugal, 1996.